The demand for embolic protection devices is growing due to several important factors, including the increasing prevalence of cardiovascular and neur ...

LEAP TA: Life Sciences is the only event entirely dedicated to transforming how biotech and pharma organizations are ...

The promising trial results may be a breakthrough for cisplatin-ineligible patients with muscle-invasive bladder cancer.

Key Points Revenue (GAAP) beat estimates by 39.5% in Q2 2025, rising to $13.1 million on substantial milestone receipts. Recurring royalty income remained modest, with only $2.6 million from ...

Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...

The global High Potency API Contract Manufacturing Market is projected to grow from USD 10.5 billion in 2025 to USD 20.7 billion by 2035, registering a compound annual growth rate (CAGR) of 7.0%, ...

EMERYVILLE, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, reported its 2025 second quarter and year to date financial results and ...

Pfizer ( PFE 0.22%) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many income investors, questions about the sustainability of the dividend persist.

The firm is touting its AI-driven foundation model's ability to predict how any patient will respond to any drug, allowing sponsors to fine-tune their trials.

Pfizer Inc. and Astellas Pharma Inc. are conducting a significant clinical study titled ‘TALAPRO-3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE V ...

GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...

The FDA cautions the outcomes described in the complaints may have no connection to the drugs or could be unexpected side effects.